María T. Bourlon

3.9k total citations · 1 hit paper
81 papers, 835 citations indexed

About

María T. Bourlon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, María T. Bourlon has authored 81 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 18 papers in Surgery. Recurrent topics in María T. Bourlon's work include Renal cell carcinoma treatment (30 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Economic and Financial Impacts of Cancer (17 papers). María T. Bourlon is often cited by papers focused on Renal cell carcinoma treatment (30 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Economic and Financial Impacts of Cancer (17 papers). María T. Bourlon collaborates with scholars based in Mexico, United States and Spain. María T. Bourlon's co-authors include Toni K. Choueiri, Robert J. Motzer, Mauricio Burotto, Cristina Suárez, Amishi Y. Shah, Elizabeth R. Kessler, Andrea B. Apolo, Yoshihiko Tomita, Bernard Escudier and Burçin Şimşek and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

María T. Bourlon

74 papers receiving 820 citations

Hit Papers

Nivolumab plus cabozantinib versus sunitinib in first-lin... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
    2022 177 citations Robert J. Motzer, Mauricio Burotto et al. profile →

Peers

María T. Bourlon
Réza Elaidi France
Q.D. Trinh United States
D.Y.C. Heng Canada
Elisabeth F.P. Peterse Netherlands
John A. Steinharter United States
Luís Más Peru
Sabeen Mekan United States
Meghara Walsh United States
Rahul R. Parikh United States
Réza Elaidi France
María T. Bourlon
Citations per year, relative to María T. Bourlon María T. Bourlon (= 1×) peers Réza Elaidi

Countries citing papers authored by María T. Bourlon

Since Specialization
Citations

This map shows the geographic impact of María T. Bourlon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María T. Bourlon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María T. Bourlon more than expected).

Fields of papers citing papers by María T. Bourlon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María T. Bourlon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María T. Bourlon. The network helps show where María T. Bourlon may publish in the future.

Co-authorship network of co-authors of María T. Bourlon

This figure shows the co-authorship network connecting the top 25 collaborators of María T. Bourlon. A scholar is included among the top collaborators of María T. Bourlon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María T. Bourlon. María T. Bourlon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monteiro, Fernando Sabino Marques, Andrey Soares, Veronica Mollica, et al.. (2024). Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 196. 104321–104321. 7 indexed citations
2.
Lima, Guadalupe, et al.. (2024). Aging‐related biomarkers in testicular cancer survivors after different oncologic treatments. Cancer Medicine. 13(18). e70200–e70200. 1 indexed citations
3.
4.
Powles, Thomas, Mauricio Burotto, Bernard Escudier, et al.. (2024). Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 9(5). 102994–102994. 31 indexed citations
5.
Bourlon, María T., Ami S. Bhatt, Gilberto Lopes, et al.. (2024). Envisioning Academic Global Oncologists: Proposed Competencies for Global Oncology Training From ASCO. JCO Global Oncology. 10(10). e2300157–e2300157. 1 indexed citations
6.
Kopp, Ray Manneh, Fabio A.B. Schutz, Fabio Kater, et al.. (2024). Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma. JCO Global Oncology. 10(10). e2300244–e2300244.
7.
8.
Choueiri, Toni K., Laurence Albigès, Philippe Barthélémy, et al.. (2024). Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. The Lancet. 404(10460). 1309–1320. 32 indexed citations
9.
Bourlon, María T., et al.. (2023). Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database. Urologic Oncology Seminars and Original Investigations. 41(8). 359.e15–359.e23. 1 indexed citations
10.
Chávarri-Guerra, Yanin, María T. Bourlon, Elena Castro, et al.. (2023). Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer. Clinical Genitourinary Cancer. 21(5). 569–573. 3 indexed citations
11.
Monteiro, Fernando Sabino Marques, Ondřej Fiala, Francesco Massari, et al.. (2023). Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study. Clinical Genitourinary Cancer. 22(2). 305–314.e3. 4 indexed citations
12.
Teuwen, Laure-Anne, et al.. (2023). Endpoints reported in phase 3 randomized clinical trials at ASCO 2022.. Journal of Clinical Oncology. 41(16_suppl). 1570–1570. 1 indexed citations
13.
Bourlon, María T., et al.. (2023). Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma. Frontiers in Oncology. 13. 1 indexed citations
14.
Bourlon, María T., et al.. (2022). Global Oncology Authorship and Readership Patterns. JCO Global Oncology. 8(8). e2100299–e2100299. 3 indexed citations
15.
Bourlon, María T., Elisabeth Meyer, Elizabeth R. Kessler, et al.. (2022). Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis. Frontiers in Oncology. 12. 926692–926692. 7 indexed citations
16.
Hernández‐Molina, Gabriela, et al.. (2021). Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell Carcinoma. PubMed. 35(3508). 486–490. 5 indexed citations
17.
18.
Bourlon, María T., et al.. (2020). Immunosenescence profile and expression of the aging biomarker (p16INK4a) in testicular cancer survivors treated with chemotherapy. BMC Cancer. 20(1). 882–882. 18 indexed citations
19.
Gralow, Julie R., Fredrick Chite Asirwa, Ami S. Bhatt, et al.. (2020). Recommendations from the ASCO Academic Global Oncology Task Force. JCO Global Oncology. 6(6). 1666–1673. 11 indexed citations
20.
Bourlon, María T., et al.. (2013). IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease?. SHILAP Revista de lepidopterología. 2013. 1–5. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Réza Elaidi Breakdown of academic impact, for papers by Q.D. Trinh Breakdown of academic impact, for papers by D.Y.C. Heng Breakdown of academic impact, for papers by Elisabeth F.P. Peterse Breakdown of academic impact, for papers by John A. Steinharter Breakdown of academic impact, for papers by Luís Más Breakdown of academic impact, for papers by Sabeen Mekan Breakdown of academic impact, for papers by Meghara Walsh Breakdown of academic impact, for papers by Rahul R. Parikh
Rankless by CCL
2026